Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

118 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Treatment of rheumatoid arthritis with a DR4/1 peptide.
St Clair EW, Cohen SB, Lee ML, Fleischmann RM, Lee SH, Moreland LW, Olsen NJ, Pratt PW, Yocum DE, Heck L, Winkelhake J, Holcenberg JS, Shulman MJ. St Clair EW, et al. Among authors: shulman mj. J Rheumatol. 2000 Aug;27(8):1855-63. J Rheumatol. 2000. PMID: 10955324 Clinical Trial.
A phase I trial of solubilized DR2:MBP84-102 (AG284) in multiple sclerosis.
Goodkin DE, Shulman M, Winkelhake J, Waubant E, Andersson P, Stewart T, Nelson S, Fischbein N, Coyle PK, Frohman E, Jacobs L, Holcenberg J, Lee M, Mocci S. Goodkin DE, et al. Neurology. 2000 Apr 11;54(7):1414-20. doi: 10.1212/wnl.54.7.1414. Neurology. 2000. PMID: 10751249 Clinical Trial.
Core outcomes set for research on the treatment of opioid use disorder (COS-OUD): the National Institute on Drug Abuse Clinical Trials Network protocol for an e-Delphi consensus study.
Karnik NS, Campbell CI, Curtis ME, Fiellin DA, Ghitza U, Hefner K, Hser YI, McHugh RK, Murphy SM, McPherson SM, Moran L, Mooney LJ, Wu LT, Shmueli-Blumberg D, Shulman M, Schwartz RP, Stephens KA, Watkins KE, Marsden J. Karnik NS, et al. Trials. 2021 Jan 28;22(1):102. doi: 10.1186/s13063-021-05051-9. Trials. 2021. PMID: 33509278 Free PMC article.
Cost-effectiveness implications of increasing the efficiency of the extended-release naltrexone induction process for the treatment of opioid use disorder: a secondary analysis.
Murphy SM, Jeng PJ, McCollister KE, Leff JA, Jalali A, Shulman M, Lee JD, Nunes EV, Novo P, Rotrosen J, Schackman BR. Murphy SM, et al. Addiction. 2021 Dec;116(12):3444-3453. doi: 10.1111/add.15531. Epub 2021 May 21. Addiction. 2021. PMID: 33950535 Free PMC article. Clinical Trial.
Prior National Drug Abuse Treatment Clinical Trials Network (CTN) opioid use disorder trials as background and rationale for NIDA CTN-0100 "optimizing retention, duration and discontinuation strategies for opioid use disorder pharmacotherapy (RDD)".
Shulman M, Weiss R, Rotrosen J, Novo P, Costello E, Nunes EV. Shulman M, et al. Addict Sci Clin Pract. 2021 Mar 6;16(1):15. doi: 10.1186/s13722-021-00223-z. Addict Sci Clin Pract. 2021. PMID: 33676577 Free PMC article. Review.
118 results